Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M

By all accounts, 2018 was a grim year for Celgene. Just months after it $CELG was forced to scrap its $710 million drug GED-0301, the big biotech announced that the FDA had handed back its NDA for pipeline star ozanimod. And the company’s public rep took a beating through the year as its stock took a sickening plunge from over the $100 mark down to $62.43 in the December trough.